Which Healthcare Company Is Best? Joe Raedle/Getty Images News Organon (NYSE:OGN) and Pfizer (PFE) both yield over 5% and are the two highest yielding pharmaceuticals. Bristol-Myers (BMY) is the only other pharmaceutical company that offers a yield above 5% that like Organon and Pfizer, can compete with similarly yielding Treasuries (i.e., those with maturities 12 months or less). Three troubling years of declining double-digit annualized returns have resulted in these well-above average yields. Pfizer ha ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 10-Q ________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commission File No. 001-40235 Organon & Co. (Exact name of registrant as specified i ...

Organon (OGN) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The power of a ch ...

Organon & Co. (NYSE:OGN) Q1 2024 Earnings Conference Call May 2, 2024 8:30 AM ET Company Participants Jennifer Halchak - Vice President, Investor Relations Kevin Ali - Chief Executive Officer Matt Walsh - Chief Financial Officer Conference Call Participants Umer Raffat - Evercore ISI Chris Shibutani - Goldman Sachs Jane Marie - BNP Paribas Jason Gerberry - Bank of America David Amsellem - Piper Sandler Balaji Prasad - Barclays Operator Thank you for standing by. My name is Mandeep and I'll be your operator ...

Organon (OGN) came out with quarterly earnings of $1.22 per share, beating the Zacks Consensus Estimate of $0.97 per share. This compares to earnings of $1.08 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 25.77%. A quarter ago, it was expected that this pharmaceutical company would post earnings of $0.80 per share when it actually produced earnings of $0.88, delivering a surprise of 10%.Over the last four quarters, the compa ...

Exhibit 99.1 Media Contacts: Karissa Peer Investor Contacts: Jennifer Halchak (614) 314-8094 (201) 275-2711 Kate Vossen Renee McKnight (732) 675-8448 (551) 204-6129 Organon Reports Results for the First Quarter Ended March 31, 2024 Jersey City, N.J., May 2, 2024 – Organon (NYSE: OGN) today announced its results for the first quarter ended March 31, 2024. "We entered this year with a clear focus: to deliver our 2024 financial targets while staying true to our mission of improving the health of women, and the ...

Organon & Co. (OGN) is scheduled to release first-quarter 2024 results on May 2, before the opening bell.In the last reported quarter, the company’s earnings beat estimates by 10%. It delivered an average earnings surprise of 5.1% in the past four quarters.  Q1 EstimatesThe Zacks Consensus Estimate for revenues is pegged at $1.57 billion. The consensus mark for earnings is pinned at 97 cents per share.Factors to NoteOrganon’s first quarter witnessed growth in the Women’s Health revenues on the back of stron ...

Wall Street analysts forecast that Organon (OGN) will report quarterly earnings of $0.97 per share in its upcoming release, pointing to a year-over-year decline of 10.2%. It is anticipated that revenues will amount to $1.57 billion, exhibiting an increase of 2% compared to the year-ago quarter.The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Organon (OGN) reports results for the quarter ended March 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on May 2. On the other ...

Environmental Liabilities and Expenditures - Environmental remediation and liability expenditures estimated at $15 million for 2024-2028[95] - Environmental liabilities totaled $19 million at December 31, 2023, and $20 million at December 31, 2022, with payments expected over the next 15 years[540] Biosimilars and Licensing Agreements - Exclusive license to commercialize biosimilars including adalimumab, bevacizumab, infliximab, trastuzumab, and etanercept under the Samsung Bioepis Agreement[96] - Gross profits shared equally in most markets, except Brazil where Samsung Bioepis receives 65% and the company receives 35%[100] - $25 million in potential future regulatory milestone payments remaining under the Samsung Bioepis Agreement as of December 31, 2023[100] - Worldwide commercialization rights for biosimilar candidates HLX11 and HLX14 secured through an exclusive license agreement with Henlius[101] - Organon licensed commercialization rights for biosimilar candidates HLX11 and HLX14 from Henlius, paying $73 million upfront and potentially up to $468 million in milestone payments[409] Financial Performance and Tax - $863 million of net deferred tax assets as of December 31, 2023, including $309 million in valuation allowances[324] - $476 million tax benefit recorded in 2023 due to the termination of a tax arrangement in Switzerland[324] - Revenues for 2023 were $6,263 million, a slight increase from $6,174 million in 2022[334] - Net income for 2023 was $1,023 million, up from $917 million in 2022[334] - Comprehensive income for 2023 was $1,046 million, compared to $866 million in 2022[337] - Net income from continuing operations for 2023 was $1,023 million, compared to $917 million in 2022 and $1,351 million in 2021[346] - Net income for 2023 was $1,023 million, with basic EPS of $4.01 and diluted EPS of $3.99[415] Research and Development - Research and development expenses increased to $528 million in 2023 from $471 million in 2022[334] - The company made a strategic investment in Claria Medical, Inc., paying $8 million upfront with an option to acquire for an additional $47 million, recognized as acquired in-process R&D[406] - Organon entered into a research collaboration with Cirqle Biomedical, paying $10 million upfront and potentially up to $360 million in milestone payments, with tiered royalties based on net sales[407][408] Assets and Liabilities - Total assets grew to $12,058 million in 2023 from $10,955 million in 2022[340] - Long-term debt decreased to $8,751 million in 2023 from $8,905 million in 2022[340] - Cash and cash equivalents decreased to $693 million in 2023 from $706 million in 2022[340] - Accounts receivable increased to $1,744 million in 2023 from $1,475 million in 2022[340] - Inventories rose to $1,315 million in 2023 from $1,003 million in 2022[340] - Total stockholders' deficit improved to $70 million in 2023 from $892 million in 2022[340] Operating Activities and Capital Expenditures - Net cash flows provided by operating activities from continuing operations were $799 million in 2023, down from $858 million in 2022 and $2,160 million in 2021[346] - Capital expenditures in 2023 were $251 million, up from $196 million in 2022 and $192 million in 2021[346] - Dividend payments in 2023 totaled $294 million, compared to $290 million in 2022 and $145 million in 2021[346] Product Portfolio and Market Launches - Organon's women's health portfolio includes Nexplanon, NuvaRing, and Follistim AQ, with Xaciato launched in the US in October 2023[351] - Organon's biosimilars portfolio includes Ontruzant, Aybintio, Brenzys, Renflexis, and Hadlima, with launches in over 20 countries for some products[351] - Organon operates six manufacturing facilities located in Belgium, Brazil, Indonesia, Mexico, the Netherlands, and the United Kingdom[348] - The company has a portfolio of more than 60 medicines and products across women's health, biosimilars, and established brands[348] - Organon's product portfolios include women's health, biosimilars, and established brands, constituting one operating segment[418] Separation from Merck and Standalone Operations - Organon became a standalone publicly traded company on June 2, 2021, following its separation from Merck[349] - The company's historical financial results prior to the separation were derived from Merck's consolidated financial statements and accounting records[349] - Net investment from Merck & Co., Inc. was reclassified to Common Stock and Accumulated Deficit as part of the Separation[360] - The Company incurred certain costs in its establishment as a standalone public company and expects to incur ongoing additional costs associated with operating as an independent, publicly traded company[362] - The Company adjusted its deferred tax balances and computed its related tax provision to reflect operations as a standalone entity as of June 2, 2021[363] - The Company's participation in the defined pension and postretirement benefit plans sponsored by Merck concluded upon the completion of the Separation on June 2, 2021[388] Rebates, Discounts, and Accruals - $417 million accrued for U.S. rebate accruals related to Medicaid and Managed Care as of December 31, 2023[327] - The Company's provision for aggregate customer discounts was $2,640 million in 2023, $2,221 million in 2022, and $2,000 million in 2021[371] - The accrued balances relative to the provisions for chargebacks and rebates in the United States were $87 million and $417 million, respectively, at December 31, 2023[371] - The accrued balances related to the provision for rebates and discounts outside the United States were approximately $126 million and $109 million at December 31, 2023 and 2022, respectively[372] Depreciation and Advertising Expenses - Depreciation expense was $120 million in 2023, $96 million in 2022, and $92 million in 2021[378] - Advertising and promotion expenses were $209 million, $255 million, and $236 million in 2023, 2022, and 2021, respectively[379] Goodwill and Lease Expenses - The Company completed the annual qualitative goodwill impairment test as of October 1, 2023 and concluded that there was no impairment to goodwill[380] - Operating lease expenses are recognized on a straight-line basis, with assets and liabilities calculated using the incremental borrowing rate, updated quarterly based on the weighted average remaining lease term and pretax cost of debt[397] Strategic Investments and Acquisitions - Organon paid an upfront payment of $50 million to Lilly for the distribution rights of Emgality® and Rayvow™ in Europe, with additional sales-based milestone payments[541] - The upfront payment and certain sales-based milestone payments are recognized as an intangible asset in Q1 2024[541] - Organon licensed global commercial rights to Xaciato from Daré Bioscience, paying $10 million upfront and potentially up to $182.5 million in milestone payments, with tiered double-digit royalties[411] - Organon acquired product rights and inventory for Marvelon™ and Mercilon™ in China and Vietnam from Bayer Healthcare, paying $95 million and recognizing $72 million as intangible assets[412][413] Share Information - The company has 255,239 thousand basic weighted average shares outstanding and 256,270 thousand diluted weighted average shares outstanding for 2023[415]